Starting from single-domain DARPin® candidates, we have continually expanded the possibilities of our DARPin® platform by creating defined biological effects. Each of these single-domain DARPin® molecules adds a new technical capability to the entire DARPin® platform. These capabilities are incorporated into new candidates in a modular fashion to elicit a custom-built therapeutic response. While we continue to characterize and expand our library of potential solutions, we are keenly focused on rapidly advancing our programs through the clinic with the ultimate objective of helping patients.
The DARPin® Platform
The DARPin® platform generates modular, customizable therapeutics with the potential to solve many of the complex biological challenges that lie at the heart of disease.
We seek to ensure a single dose can provide the right duration of effect and concentration in the body via a tunable half-life. We use this capability across our oncology and antiviral programs.
A multi-domain DARPin® can block multiple targets at once. No single mutation in a virus or cancer cell is likely to completely stop this ‘multi-blocking’, potentially giving our candidates broader efficacy and staying power against evolving targets.
We deliver a precision approach to anti-tumor immunity through combining an immune-stimulating DARPin® with a DARPin® that localizes the immune activation to the tumor environment. The intended result is enhanced efficacy with lowered risk of damage to healthy tissues.
Through multivalent targeting of viral surface proteins, we can effectively prevent viral fusion and therefore infection of target cells – this neutralization of viral particles is a feature of our leading anti-Covid 19 candidate, ensovibep.
The binding surfaces of a DARPin® exert a unique molecular ‘grip’ on their targets, which can allow targeting of certain proteins that other biologic modalities like antibodies struggle with.
We can bring together immune cell surface proteins that only activate in clusters. A DARPin® candidate can link them to proteins that already cluster on the surface of tumors. The resulting aggregation initiates immune activation with reduced risk of systemic inflammation.
With vast libraries of potential DARPin® molecules that can be rationally and rapidly combined and screened, we are constantly working to expand our technical capabilities and further unlock the potential of our DARPin® platform to create new possibilities for novel therapeutics.